SCHEMBL30797747

SCHEMBL30797747

CC(C)(C)OC(=O)NCCCCOCCNc1cc(B2OC(C)(C)C(C)(C)O2)cc2c1cnn2C1CCCCO1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ATR Q13535 3/20 0.41
▸ PRMT5 O14744 1/20 0.36
▸ WDR77 Q9BQA1 1/20 0.36
▸ FPR3 P25089 2/20 0.34
▸ FPR2 P25090 2/20 0.34
▸ USP30 Q70CQ3 1/20 0.33
▸ BRD4 O60885 2/20 0.33
▸ KRAS P01116 1/20 0.32
▸ DDB1 Q16531 3/20 0.32
▸ CRBN Q96SW2 3/20 0.32
▸ RXRA P19793 1/20 0.32
▸ RXRB P28702 1/20 0.32
▸ RXRG P48443 1/20 0.32
▸ TLR2 O60603 1/20 0.32
▸ TLR1 Q15399 1/20 0.32
▸ HRH3 Q9Y5N1 1/20 0.31
▸ MIF P14174 1/20 0.31
▸ CNR2 P34972 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27376667 1.00 ATR (0.41) ATRPRMT5WDR77FPR3FPR2
SCHEMBL30869047 0.90 ATR (0.33) ATRPRMT5WDR77USP30KRAS
SCHEMBL30869075 0.89 ATR (0.40) ATRPRMT5WDR77USP30BRD4
SCHEMBL30797881 0.88 ATR (0.47) ATRPRMT5WDR77FPR3FPR2
SCHEMBL30797730 0.86 ATR (0.44) ATRFPR3FPR2BRD4DDB1
SCHEMBL27376660 0.84 PRMT5 (0.37) PRMT5WDR77FPR3FPR2USP30
SCHEMBL30869074 0.84 ATR (0.43) ATRFPR3FPR2BRD4RXRA
SCHEMBL30869124 0.84 ATR (0.41) ATRPRMT5WDR77FPR3FPR2
SCHEMBL30869078 0.83 ATR (0.45) ATRFPR3FPR2BRD4DDB1
SCHEMBL30797851 0.83 ATR (0.43) ATRFPR3FPR2BRD4DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584266-A1 NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF Cambridge Enterprise Limited (GB) 2025-07-16 — — EP disclosed
EP-4584249-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS Cambridge Enterprise Limited (GB) 2025-07-16 — — EP disclosed
WO-2024052701-A1 NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-03-14 — — WO disclosed
WO-2024052702-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-03-14 — — WO disclosed
Send feedback